SensID GmbH Introduces the first ESR1 Mutations Reference Set for Cell-Free DNA Mutation Detection

15. November 2023Uncategorized

Rostock, 2023 Nov 23 – SensID GmbH, a leading provider of quality control materials for molecular diagnostic testing, is proud to announce the launch of a “ESR1 Reference Set (1% AF cfDNA).” This cutting-edge product is specifically designed as quality control material for laboratories currently developing/implementing ESR1 assays, making SensID the first in the market … Read More

Pathogen diagnostic reference materials

14. October 2020Press releases

Rostock, October 14th, 2020, SensID and Noscendo combine forces to develop a contamination-free reference material with known human DNA quantity and virus status for clinical system validation. The reference material is developed by SensID and tested by Noscendo to be positive for standard microbial DNA and completely free of contaminating microbial DNA. The reference materials will serve … Read More

SAGA Diagnostics and SensID collaborate on ultra-low allelic frequency control reagents for cancer mutations

15. July 2020Uncategorized

Rostock and Lund, 15 of July 2020 SensID GmbH, headquartered in Rostock, Germany, is a specialist for development and production of reference control materials for clinical genomics. SAGA Diagnostics AB, headquartered in Lund, Sweden, is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients.  Today the two companies announce a … Read More

SensID product development in collaboration with Qiagen

21. April 2020Press releases

Rostock, 7th of April 2020  SensID GmbH, a Germany based provider of controls and reference materials for clinical genomics, today announces that it has developed a set of controls for the US FDA approved and CE-IVD marked therascreen PIK3CA RGQ PCR Kits from QIAGEN.  The CE-IVD therascreen PIK3CA RGQ PCR Kit was launched in Europe in February 2020 as an aid to the identification of activating PIK3CA mutations in samples of either FFPE tumour tissue or … Read More